Endocytosis of excitatory glutamate receptors from the postsynaptic plasma membrane plays a fundamental role in synaptic function and plasticity. In a recent study published in Neuron, Lu et al. (2007) describe protein interactions that link zones of receptor endocytosis directly to the postsynaptic scaffold and propose that local trafficking of receptors facilitated by these endocytic zones is required to maintain synaptic responsiveness.
Cancer cells harbor vast numbers of genetic and epigenetic alterations including point mutations, deletions, rearrangements, amplifications, translocations, and transcriptional silencing. As large sequencing efforts have shown, many of these alterations are likely to be coincidental (Sjoblom et al., 2006) , whereas a select few arise nonrandomly and drive the cancer phenotype. Among this latter category are activating mutations in oncogenes, such as receptor tyrosine kinases and the small GTPase Ras. Because many cancers require increased activity of these oncogenes for tumor initiation and maintenance, this dependence has been coined "oncogene addiction" (Weinstein, 2002) . Substantial efforts have been devoted to the development of cancer therapeutics targeting oncogenes, and notable successes for this strategy include the tyrosine kinase inhibitors Gleevec (which blocks BCRAbl) and Iressa (which blocks EGFR).
Despite the focus on oncogenes as targets of cancer therapeutics, there are solid genetic arguments based on experimental evidence for a larger class of drug targets that are not oncogenes but if targeted could be equally effective at treating cancer. For example, not every protein in a given tumorpromoting pathway can be activated by mutations or overexpressed to an extent that directly promotes oncogenesis. However, many if not all of these proteins can be rate-limiting to their pathways and represent potential drug targets. We term this phenomenon "non-oncogene addiction" in reference to the increased dependence of cancer cells on the normal cellular functions of certain genes, which themselves are not classical oncogenes.
In this issue, Lindquist and her colleagues illustrate an example of nononcogene addiction by uncovering a surprising and critical role of heatshock factor 1 (HSF1) in tumorigenesis (Dai et al., 2007) . HSF1 is a transcription factor that is activated by a variety of protein-denaturing cellular stresses including heat and hypoxia. In turn, HSF1 controls the expression of heatshock proteins that promote protein refolding, prevent protein aggregation, and target misfolded proteins for destruction. The investigators demonstrate that HSF1 deficiency in mice protects against tumorigenesis both in the classical chemical skin carcinogenesis model and in a genetic model driven by a clinically relevant oncogenic mutation in p53 (p53 R172H ). Although not completely tumor-free, mice lacking HSF1 exhibit a much lower incidence of tumors, display reduced tumor burden, and exhibit increased survival when compared to their wild-type littermates. or PDGF-B transduction, and exhibit increased cell death following transduction of c-MYC or Large T Antigen. These lines of evidence suggest that HSF1 provides critical relief to the stress experienced by cancer cells.
One plausible mechanism by which HSF1 functions is through the induction of the heat-shock protein HSP90, which has been implicated in tumorigenesis and is overexpressed in a variety of cancers (Whitesell and Lindquist, 2005) . HSP90 forms a complex with its substrate targeting subunit Cdc37. This complex stabilizes a number of key regulators of cell proliferation and survival such as the kinases Cdk4, HER2/ErbB2, and Akt. The anticancer drug geldanamycin inhibits the chaperone activity of HSP90 by interacting with HSP90's ATP-binding pocket, leading to destabilization of its client Heat-shock factor 1 (HSF1) is a transcription factor that is activated upon proteotoxic stress and coordinates induction of the heat-shock response. In this issue, Dai et al. (2007) show that HSF1 is a potent modifier of tumorigenesis and is required for tumor initiation and maintenance in a variety of cancer models. These findings add HSF1 to a growing list of non-oncogenes that could be exploited as cancer drug targets.
proteins. Reduction of these client kinases has been proposed to mediate geldanamycin's antitumorigenic properties. Similarly, the authors show multiple signaling defects in HSF1-deficient MEFs including attenuated MAPK signaling by downregulation of KSR (a scaffold for the Erk-MAPK pathway), increased mitogen dependence of protein translation due to decreased ribosome biogenesis and mTOR signaling, and increased tolerance of glucose deprivation indicating a possible shift from aerobic glycolysis to oxidative phosphorylation. Although a supporting role for HSF1 in an oncogenic melodrama is attractive, a model for non-oncogene addiction with potentially greater ramifications for cancer treatment would argue that cancer cells experience high levels of proteotoxic stress and rely upon stress response pathways for survival and proliferation. Cancer cells are known to exhibit high levels of reactive oxygen species, spontaneous DNA damage, and aneuploidy, each of which represents a form of cellular stress. The importance of aneuploidy as a factor in cellular stress was established in a recent study in yeast where the presence of even a single extra chromosome induced activation of the environmental stress and heatshock responses (Torres et al., 2007) . Aneuploidy in cancer cells is likely to result in severe imbalances of components of protein complexes. These imbalances might burden chaperone and proteasome pathways, thus compromising folding of essential cellular proteins and leading to the higher levels of heat-shock proteins observed in many tumors (Whitesell and Lindquist, 2005) . Thus, cancer cells are highly dependent upon these general stress responses, providing examples of nononcogene addiction (Figure 1) .
A variety of cancer drugs exist that either directly inactivate components of these responses (such as geldanamycin) or exacerbate the stress (such as the proteasome inhibitor Velcade) to accomplish their antitumorigenic effects. In accordance with this notion, aneuploidy in yeast increases sensitivity to both geldanamycin and proteasome inhibitors (Torres et al., 2007) . Similarly, blocking the DNAdamage response with inhibitors of the checkpoint kinase Chk1 shows promise in the preferential killing of cancer cells (Chen et al., 2006; Tse et al., 2007) . Although it seems counterintuitive that a pathway that normally serves to restrain proliferation would protect a cancer cell, the DNA repair and maintenance of genomic stability afforded by this pathway could save a cancer cell from death due to the occurrence of persistent DNA damage. In support of this notion, breast cancer cells from Brca2-deficient tumors show a strong dependency on the DNA stress protein poly ADPribose polymerase (PARP). Inhibition of PARP in these cells aggravates the DNA-damage stress response to the point of lethality (Bryant et al., 2005) . Thus, activation of the DNA-damage response in tumor cells can be viewed as a type of non-oncogene addiction that critically supports tumor growth.
The landscape of non-oncongene addiction is vast and unexplored and is likely to provide a rich harvest for new cancer drug targets. By definition, genes involved in such pathways will evade detection by sequencing. The extensive alterations in gene copy number and transcriptional profile found in most tumors make it difficult to pinpoint functionally critical pathways for non-oncogene addiction. However, recent advances in RNA interference (RNAi) have begun to systematically reveal the dependence of tumors on non-oncogene addiction pathways through cancerlethal screens. Through such unbiased genetic screens that identify non-oncogenes like HSF1, whose functions are critical to cancer cells but dispensable to normal cells, the hidden stresses and vulnerabilities associated with the malignant lifestyle should be revealed for new opportunities in cancer therapeutics. Cancer cells exhibit increased dependence on several stress response pathways including those for oxidative damage, DNA damage, and heat-shock. The heat-shock response in tumor cells occurs through HSF1 activation and results in transcription of heat-shock proteins (HSPs) and other chaperones. Upregulation of the heat-shock response in cancer cells could alleviate the negative effects of increased protein dosage due to aneuploidy, competition among proteins for access to chaperones, increased protein turnover, and proteasome stress. Similarly, elevated levels of reactive oxygen species (ROS) and aberrant DNA replication in cancer cells lead to persistent DNA damage that requires the DNA-damage response to provide genetic stability and cell survival. A star (*) denotes sites of therapeutic intervention in these pathways where inhibitors of non-oncogenes such as HSP90 (geldanamycin), the proteasome (Velcade), or Chk1 (CHIR-124) exploit these dependencies of cancer cells to achieve their therapeutic efficacy. Additional stresses in cancer cells (not shown) include metabolic/energy stress, ER stress, mitochondrial stress, and membrane stress.
Synaptic plasticity, widely considered the cellular basis for learning and memory, is mediated in the hippocampus largely by changes in the number of AMPA-type glutamate receptors (AMPARs) on individual "spines" protruding from the dendritic plasma membrane (Malenka and Bear, 2004) . Each spine mediates a distinct synaptic input, and under physiological conditions, plasticity occurs selectively at some synapses but not others. How do neurons modify the number of AMPARs selectively on individual spines?
In a recent issue of Neuron, Lu et al. (2007) provide an important clue based on their studies of AMPAR endocytosis. Clathrin-dependent endocytosis of AMPARs is stimulated by synaptic activity and occurs primarily in regions of the plasma membrane termed postsynaptic endocytic zones (EZs). EZs are localized in the spine adjacent to a dense network of scaffold proteins called the postsynaptic density (PSD) (Figure 1) . Lu et al. hypothesized that Homer-a protein that is highly expressed in neurons and binds to both the PSD-embedded protein Shank and the endocytic protein dynamin-3 (Gray et al., 2003; Tu et al., 1999) -could be the lynchpin in a series of interactions that physically links the EZ to the PSD. To test this hypothesis, they inhibited the interaction of Homer with either Shank or dynamin-3 in cultured neurons by overexpressing mutant versions of dynamin-3 or Shank that could not bind to Homer and then used fluorescence microscopy to examine effects on the localization of EZs. Consistent with their hypothesis, EZs became mislocalized away from synapses when interactions between dynamin-3 and Homer, or Homer and Shank, were disrupted. Furthermore, depleting endogenous dynamin-3 from hippocampal neurons using RNA interference also caused the mislocalization of EZs. In these neurons, expression of wild-type dynamin-3-but not dynamin-3 mutants lacking domains required for oligomerization or binding to Homer-rescued appropriate localization of EZs adjacent to the PSD.
These results indicate that a multimeric protein complex involving Homer keeps the EZ closely situated at the periphery of dendritic spines. But what is the functional significance of this exquisite spatial organization? Lu et al. observed that mislocalization of EZs selectively inhibited AMPAR endocytosis but not clathrin-dependent endocytosis of transferrin, a distinct cargo that is endocytosed primarily from extrasynaptic regions. More surprisingly, despite markedly delayed endocytosis of AMPARs in neurons where EZ localization was disrupted, the steady-state number of AMPARs present on spines actually decreased. This result, established initially by antibody staining,
